remdesivir

remdesivir
Name	Remdesivir
Routes of administration	Intravenous
Class	Antiviral nucleotide analogue

remdesivir is an antiviral nucleotide analogue prodrug developed for treatment of RNA virus infections. It was investigated in studies spanning outbreak responses and pandemic preparedness and evaluated by multiple academic, industry, and public health organizations. Clinical development intersected with prominent research consortia, pharmaceutical firms, regulatory agencies, and global health initiatives.

Medical uses

Remdesivir has been administered for treatment of severe acute infections caused by RNA viruses in hospitalized patients, often alongside supportive care from institutions engaged in critical care and infectious disease management such as Johns Hopkins Hospital, Mayo Clinic, University of Oxford, Stanford Health Care, and Massachusetts General Hospital. Emergency and compassionate use programs coordinated with agencies including World Health Organization, Centers for Disease Control and Prevention, National Institutes of Health, European Medicines Agency, and national health ministries defined eligibility criteria that often reflected guidance from specialist societies like the Infectious Diseases Society of America and the American Thoracic Society. Use cases evaluated included treatment of patients with respiratory failure, hypoxemia, or systemic viral replication detected in studies run by networks such as the National Institute of Allergy and Infectious Diseases and collaborative trials organized by academic centers and contract research organizations.

Mechanism of action

The pharmacophore of the drug targets viral polymerase complexes conserved across several RNA virus families studied by virology groups at institutions like Centers for Disease Control and Prevention, Pasteur Institute, Rockefeller University, Harvard University, and University of Cambridge. The active triphosphate metabolite competes with natural nucleotides during replication within the viral replication–transcription complex explored in structural studies by laboratories associated with Max Planck Society, Cold Spring Harbor Laboratory, and Scripps Research Institute. Biochemical assays performed in collaboration with teams from National Institute of Standards and Technology and structural biology units using techniques developed at European Molecular Biology Laboratory and Argonne National Laboratory informed models of chain termination and delayed incorporation into nascent RNA. Computational studies by groups at Massachusetts Institute of Technology and California Institute of Technology complemented cryo-electron microscopy from centers like MRC Laboratory of Molecular Biology.

Pharmacology

Pharmacokinetic and pharmacodynamic characterization involved clinical pharmacology units at organizations such as GlaxoSmithKline, Gilead Sciences, Pfizer, and university clinical trial centers including University Hospital Geneva and Vanderbilt University Medical Center. Intravenous administration leads to systemic distribution monitored by analytical laboratories at FDA-recognized bioanalytical centers and university cores, with metabolism assessed by teams using mass spectrometry platforms developed at Oak Ridge National Laboratory and Lawrence Berkeley National Laboratory. Drug–drug interaction studies incorporated reagents and reference standards from World Health Organization and methods standardized by Clinical and Laboratory Standards Institute. Population PK models were generated by collaborations with groups at Duke University and University of Pennsylvania to inform dosing in adults and special populations evaluated in settings such as King's College Hospital and Royal Free Hospital.

Adverse effects and safety

Safety signals were characterized in pharmacovigilance systems coordinated by regulatory bodies including Food and Drug Administration, European Medicines Agency, and national pharmacovigilance centers in Japan, Canada, and Australia. Reported adverse events observed in clinical cohorts managed at Cleveland Clinic, Johns Hopkins Hospital, and tertiary centers included laboratory abnormalities and clinical events monitored per guidelines from World Health Organization and specialty societies like the American College of Physicians. Monitoring protocols referenced standards from International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and adverse event coding systems maintained by Uppsala Monitoring Centre.

History and development

Early discovery and preclinical evaluation occurred within antiviral research programs linked to academic centers and biotech firms with collaborations involving teams at Gilead Sciences, University of California, San Francisco, Princeton University, and government laboratories such as United States Army Medical Research Institute of Infectious Diseases and National Institutes of Health. Development accelerated during outbreak responses that engaged international networks including World Health Organization emergency research platforms and partnerships with philanthropic funders such as the Bill & Melinda Gates Foundation and public–private consortia modeled on initiatives like Coalition for Epidemic Preparedness Innovations. Preclinical efficacy was reported in animal models maintained at facilities like Rockefeller University and Yale School of Medicine.

Regulatory approval and guidelines

Regulatory review and emergency authorizations involved agencies such as Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, and national ministries of health in jurisdictions including United States, United Kingdom, European Union member states, and Japan. Treatment guidance that referenced trial data was issued by organizations including World Health Organization, Infectious Diseases Society of America, National Institutes of Health, and country-level public health authorities coordinating policy with academic guideline panels at University of Toronto and University of Sydney.

Clinical trials and efficacy studies

Major randomized and platform trials that assessed clinical endpoints were conducted by trial networks and institutions such as National Institutes of Health-supported consortia, WHO Solidarity Trial collaborators, multicenter trials organized by University of Oxford and academic clinical trial units at Columbia University, Imperial College London, Brigham and Women's Hospital, and Karolinska Institutet. Outcome measures included virologic endpoints, time to recovery, and mortality evaluated using statistical methods developed by groups at Johns Hopkins Bloomberg School of Public Health and London School of Hygiene & Tropical Medicine. Systematic reviews and meta-analyses synthesizing trial results were published with contributions from researchers at Cochrane Collaboration, BMJ Publishing Group, and major medical journals including The Lancet, New England Journal of Medicine, and JAMA.

Category:Antiviral drugs